Company / Cash & Equivalents
Fulgent Genetics, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$50.2M
FY2025
5-year range
$50.2M / $164.9M
FY2021-FY2025
Trend
-9.0%
vs FY2024
Sector context
#130 of 148
Health Care
What the data says
Fulgent Genetics, Inc.'s cash & equivalents of $50M is lower than 88% of companies in the Health Care sector (FY2025). Declined from $80M to $50M over the past 2 years.
Based on SEC 10-K filings.
$50M in FY2025 with a 5-year CAGR of -10.5%.
Declined from $80M to $50M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -14.2%
- 5-Year CAGR
- -10.5%
- 10-Year CAGR
- -
Sector benchmark
Bottom 12% in Health CareTop 88% of 148This company $50.2M Sector average $1.2B
▼
-95.7% below sector average
Key checks
Key Insights
- 5-year CAGR of -10.5%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 9.0% year-over-year.
- Ranks #130 out of 148 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 5.28 (safe zone, above 2.9 threshold)
- Negative profit margin: -15.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $50.2M | -9.0% |
| FY2024 | $55.1M | -30.6% |
| FY2023 | $79.5M | +0.0% |
| FY2022 | $79.5M | -51.8% |
| FY2021 | $164.9M | +88.6% |
| FY2020 | $87.4M | +630.7% |
| FY2019 | $12.0M | +84.4% |
| FY2018 | $6.5M | +0.0% |
| FY2017 | $6.5M | -17.8% |
| FY2016 | $7.9M | +1514.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026